Professor Hao wore glasses, a suit and tie, looked very elegant and had a very amiable face.
Two assistants came over with computers and helped to display the lecture PPT content.
"Dear colleagues, today I will give you a special lecture on the latest research progress of PTCD intrabiliary radiotherapy. This is a technology introduced from abroad. It has been developed in our country for nearly ten years. It is a technology that is not widely used in China but is relatively mature. The technology currently used in our country is basically to insert iridium 192 wire into the bile duct as a wire source. As for the placement and distance from the tumor, these require more detailed research. Our hospital has been using this technology for more than eight years, and I have some experience in this regard that I would like to share with my colleagues."
Although he is a professor, he is very humble when discussing academic issues and speaks in a steady and scholarly manner.
The audience was basically silent, and everyone was studying quietly.
"Choledochocarcinoma is not very sensitive to chemotherapy. This technology was not first used for cholangiocarcinoma. However, after being used in clinical practice, there are many encouraging findings. For example, if the tumor is smaller than 1.5 cm, only intracavitary irradiation can be used, and the survival period can be extended. For tumors larger than 1.5 cm, it is best to add extracavitary irradiation, which is definitely much better than simple extracavitary irradiation. The patient's survival period can also be relatively extended."
Prof. Hao probably felt that the conference room was a bit stuffy, so he adjusted the atmosphere and said to the audience: "If you have any ideas or suggestions from colleagues, you can ask questions and speak at any time. Just raise your hands so we can see it."
When they heard him say this, some people raised their hands.
The assistant immediately handed the microphone to the man.
...
...
"Excuse me, Dr. Hao, is this technology only used in palliative care? Our hospital once wanted to try to apply it before and after surgery. I don't know if your hospital has tried this practice and research. I want to know if it is meaningful for shrinking tumors before surgery and removing residual tumor tissue after surgery. We have read relevant papers and some colleagues have done similar research, but for some reason there are very few cases. Can you please answer the relevant questions, Professor Hao?"
The doctor who asked the question asked a series of questions, all of which were practical questions full of useful information, which shows that he is definitely a frontline doctor.
Professor Hao smiled, asked the other party to sit down, and explained: "Regarding the questions you asked, especially the last question, why this kind of preoperative and postoperative application is relatively rare. The main reason is that we have more than one technology to shrink the tumor before surgery and remove residual tumor tissue after surgery. Compared with other technologies, as I said at the beginning, bile duct cancer is less sensitive to radiotherapy. With advanced chemotherapy drugs, we can certainly use chemotherapy drugs to shrink the tumor and remove residual tumor tissue. This technology can only be said to have certain advantages in palliative treatment, in that it can locally eliminate the tumor. If there are more advanced drugs in the future, there will be no need for stents to maintain drainage."
After the expert finished speaking, the frontline doctors at the grassroots level were inspired and stood up to express their gratitude again.
The lecture continued. The dose problem, the irradiation distance problem, and various research tables were listed on the PPT. Some of the audience members took notes while watching. Although this technology is not considered surgery, auxiliary therapy is also very important for surgery. When some patients really cannot undergo surgery, doctors really need to find other ways.
Continue read on readnovelmtl.com
